New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTAGIOAgios Pharmaceuticals announces AG-221 orphan drug designation
Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia. AG-221 is an oral IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
15:06 EDTAGIOAgios Pharmaceuticals announces orphan drug designation of AG-348
Subscribe for More Information
14:03 EDTAGIOAgios pyruvate kinase deficiency treatment granted FDA orphan status
The FDA designated an allosteric activator of the red blood cell-specific form of pyruvate kinase from Agios Pharmaceuticals as an orphan treatment of pyruvate kinase deficiency, the FDA stated in a post to its site. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use